AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00%

TTX Tetratherix Limited

Healthcare · Biotechnology · website · 15 employees
$7.70
52wk 3.09 – 8.08
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About Tetratherix Limited

Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally. The company manufactures and commercialize medical device in the areas of bone regeneration, tissue spacing, and tissue healing applications through its Tetramatrix platform technology. Tetratherix Limited was incorporated in 2015 and is based in Alexandria, Australia.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$408.38M
P/E (trailing)
P/E (forward)
-51.12
EPS (trailing)
-0.40
Dividend yield
Payout ratio
0.0%
Beta
EV / EBITDA
-49.42
Price / Book
15.91
ROE
-150.0%
Operating margin
-339.9%
Net margin
0.0%
Total cash
$21.56M
Total debt
$11.21M
Current ratio
12.13
Debt / Equity
0.46
Free cash flow
$-9.97M
Avg volume
20,433
Latest annual results (FY ending 30 Jun 2025)
  • Revenue
  • Gross profit
  • Operating income-$6.90M
  • Net income-$9.43M
  • Diluted EPS-0.36
  • Free cash flow-$3.27M
  • Net debt-$27.30M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $59.53B 14.0
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9